Dr. Fernando C. Fervenza, MD

Dr. Fervenza practices at Mayo Clinic Breast Diagnostic Clinic in Rochester, Minnesota.

Dr. Fervenza's NPI, 1356313522, was assigned on February 2, 2006. Dr. Fervenza graduated from Federal University of Rio Grande do Sul School of Medicine in 1982. Dr. Fervenza's Minnesota license number on file is 40692.

Dr. Fervenza's primary practice is Mayo Clinic Breast Diagnostic Clinic, at 200 First Street SW, Rochester, MN 55905. The practice phone is (507) 284-5968.

Dr. Fervenza's primary practice is Mayo Clinic Breast Diagnostic Clinic in Rochester, Minnesota. Dr. Fervenza is also affiliated with Mayo Clinic Hospital, Saint Marys Campus. The medical group on file is Mayo Clinic. Dmand AI also links Dr. Fervenza to 1 more clinical lab and 1 hospice, each named with a free account. Dr. Fervenza's employer is on file too: a breast imaging center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Fervenza practices, 4 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Fervenza's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Fervenza is board certified in nephrology by the American Board of Internal Medicine. Dmand AI has Dr. Fervenza's licenses on file in 2 states: Minnesota and Alabama.

Dmand AI lists chronic kidney disease and kidney disease among the conditions Dr. Fervenza treats.

CMS data shows 84 Medicare services from Dr. Fervenza across 2 procedure codes in 2024, all of them office visits, for 76 Medicare patients. Medicare paid $6,127 for them. Every service was in an office.

CMS counts 76 Medicare patients who saw Dr. Fervenza in 2024. The largest group is 65 to 74, with 43 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. Their average risk score is 1.70, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Fervenza's median patient age at 62, with 37% women.

In 2024, Dr. Fervenza wrote 322 Medicare Part D claims for 69 patients. 94% of them were for generic drugs. CMS names the drug for 182 of them, across 8 drugs with 11 or more claims each, at $17,998 in total drug cost. In 2023, CMS named 188 claims across 9 drugs.

Dr. Fervenza accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Fervenza as offering telehealth.

Dmand AI links 304 papers to Dr. Fervenza, published from 2004 to 2025. 2023 was the busiest year, with 20. The most frequent topics are Kidney, Rituximab and Biopsy. Dr. Fervenza has published most often in Nephrol Dial Transplant. Dr. Fervenza's most frequent co-authors are Nelson Leung, MD, Ladan Zand, MD and Lynn Diane Cornell, MD.

Dmand AI links Dr. Fervenza to 11 clinical trials, 2 of them phase 1 studies. 1 is still active or recruiting. Conditions studied include Glomerulonephritis, Glomerulonephritis, Membranous and Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Mayo Clinic sponsors the most, 7. Open Payments lists research payments to Dr. Fervenza that name 1 trial.

CMS Open Payments shows 87 general payments to Dr. Fervenza from 18 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 96% of the total. Alexion Pharmaceuticals, Inc. paid the most, $20,444. It also lists 7 research payments totaling $2,684 from 2016 to 2024, naming 1 clinical trial.

Dmand AI lists 15 awards for Dr. Fervenza, most recently Fellow in 2011.

Dr. Fervenza graduated from Federal University of Rio Grande do Sul School of Medicine in 1982. Dr. Fervenza is a member of ASN, European Renal Association, ISN and NKF.

Dr. Fervenza is in network with 17 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.